ICF invests €10M in Asabys fund II, which has already 3 companies in its portfolio

by Institut Català de Finances (ICF)

​Asabys has announced that the Institut Català de Finances (ICF) has joined its new venture capital fund, Sabadell Asabys Health Innovation Investments II (Sabadell Asabys II), with 10 million euro...

Read more

AbolerIS Pharma Announces €27 Million in Series A Financing led by Caixa Capital Risc to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

by Caixa Capital Risc

AbolerIS Pharma, a Belgian biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3 million Series A ...

Read more

Aliath Bioventures appoints Dr Philippe Monteyne and announces additional hires to further strengthen its Life Sciences Impact business

by AltamarCAM Partners

Aliath Bioventures, the healthcare impact investment platform of AltamarCAM Partners, appoints Philippe Monteyne, MD, PhD as a new Partner to reinforce the company’s healthcare investment team.

Read more

The companies of the BCN Health Booster accelerator raise €51.8 M in the first year of the programme

by Parc Científic de Barcelona (PCB)

The 1st generation of companies participating in BCN Health Booster accelerator raised €51.8 million of public and private funding during 2022 (the first year of its launch), a figure that represent...

Read more

ADmit therapeutics closes a €5.4 million funding round led by Clave Capital, through its Clave Innohealth f.c.r. fund.

by CLAVE

ADmit has secured a €5.4 million equity round with Clave Capital as the lead investor, with significant support from the EIC Fund and the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics Acc...

Read more

Laminar Pharma capta 8,8 millones para luchar contra el tumor cerebral

by Professional Newco

La mayor parte de esta inversión proviene de un grupo de inversores con sede en Alicante, encabezados por el family office del abogado David Devesa, y también con la participación adicional de la f...

Read more

Healthcare M&A: Where Capital Meets Care In A Post-Pandemic World

by Translink Corporate Finance

In the healthcare sector, renowned for its resilience and appeal to astute investors, a distinctive shift is underway. Investment funds have assumed a prominent role in M&A activities, fostering R&D p...

Read more

Asabys’ portfolio company Agomab Raises $100 Million Series C from Fidelity, EQT Life Sciences, Canaan and KKR

by Asabys Partners

Agomab Therapeutics has announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company (FMR), with participation from new investors EQ...

Read more

Sidekick Health, backed by Asabys Partners, announces landmark acquisition, expanding its portfolio to offer regulated Prescription Digital Therapeutics

by Asabys Partners

Sidekick Health’s recent success in closing its Series B fundraising round in May 2022 laid the foundations for the company to accelerate innovation and drive even greater impact in the digital heal...

Read more

SpliceBio, backed by Ysios Capital, Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

by Ysios Capital

SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the signing of an exclusive collaboration and licensing agre...

Read more

CRB Inverbío amplía su portafolio con un tercer fondo dedicado a proyectos de Salud Digital con un tamaño de hasta €40 millones

by CRB Inverbío SA SGECR

CRB Inverbío amplía su portafolio con un tercer fondo de capital riesgo dedicado a proyectos de Salud Digital tanto españoles como europeos de tamaño de hasta 40 millones de euros, y expande con e...

Read more

Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, closes a €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures

by Ysios Capital

Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched today with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

tuTECHÔ se convierte en la primera empr...

by EY - Ernst & Young

tuTECHÔ, empresa social que lucha contra el sinhogarismo en España, ...

Photos Stream